CRISPR Therapeutics AG (CRSP) Depreciation & Amortization (CF) (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 8.8% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $19.1 million (down 0.52% YoY), and the FY2025 full-year result was $19.5 million, up 1.14% from the prior year.
• Depreciation & Amortization (CF) retreated to $4.3 million in Q1 2026, from $5.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $7.3 million in Q2 2022 to a low of $4.3 million in Q1 2026.
• A 5-year average of $5.1 million and a median of $4.9 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) jumped 122.43% in 2022 and sank 31.75% in 2023, its largest moves.
• Tracing CRSP's Depreciation & Amortization (CF) over 5 years: stood at $5.8 million in 2022, then dropped by 16.18% to $4.9 million in 2023, then decreased by 1.18% to $4.8 million in 2024, then increased by 16.91% to $5.7 million in 2025, then fell by 23.71% to $4.3 million in 2026.
• Business Quant data shows CRSP's Depreciation & Amortization (CF) at $4.3 million in Q1 2026, $5.7 million in Q4 2025, and $4.4 million in Q3 2025.